2.39  -0.04 (-1.65%)		07-28 16:00
Open: 2.36 High: 2.44 Volume: 86,973		Pre. Close: 2.43 Low: 2.15 Market Cap: 182(M)

Short term
Mid term
Targets	6-month :	3.21	1-year :	3.75
Resists	First :	2.75	Second :	3.21
Pivot price	2.36
Supports	First :	2.02	Second :	1.58
MAs	MA(5) :	2.5	MA(20) :	2.3
	MA(100) :	2.14	MA(250) :	18.69
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	47.5	D(3) :	61.5
RSI	RSI(14): 55.8
52-week	High :	67	Low :	1.42

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MENS ] has closed below upper band by 45.4%. Bollinger Bands are 12.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.44 - 2.46	2.46 - 2.47
Low:	2.12 - 2.14	2.14 - 2.15
Close:	2.37 - 2.39	2.39 - 2.41

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

Mon, 27 Jul 2026
Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey

Thu, 23 Jul 2026
Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative

Thu, 23 Jul 2026
Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan

Tue, 10 Feb 2026
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop - Yahoo Finance

Mon, 29 Dec 2025
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st

Fri, 19 Dec 2025
Jyong Biotech Responds to Share Price and Volume Movement - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	74 (M)
Shares Float	27 (M)
Held by Insiders	62.2 (%)
Held by Institutions	0.7 (%)
Shares Short	241 (K)
Shares Short P.Month	327 (K)

EPS	-0.06
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.35
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-12 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.04
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	4 (M)

PE Ratio	-39.84
PEG Ratio	0
Price to Book value	-7.03
Price to Sales	0
Price to Cash Flow	-58.36

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.